National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

About this update from Rigel Pharmaceuticals, Inc.

[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 18, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that REZLIDHIA™ (olutasidenib) has been added by the National Comprehensive Cancer Network® (NCCN®) to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for acute myeloid leukemia (AML). REZLIDHIA (olutasidenib) is now included as a recommended targeted therapy for adult patients with relapsed/refractory (R/R) AML with isocitrate dehydrogenase-1 (IDH1) mutation.\n\"We are pleased that REZLIDHIA was quickly added to the NCCN Guidelines® for AML, receiving important recognition as an appropriate treatment option for adult R/R AML patients with an IDH1 mutation,\" said Raul Rodriguez, president and CEO of Rigel. \"Inclusion in the NCCN Guidelines for AML reinforces the strength of the data, which supports the safety and efficacy of REZLIDHIA.\"\nIn December 2022, the U.S. Food and Drug Administration (FDA) approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test. REZLIDHIA is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.\nThe NCCN is a not-for-profit alliance of 32 leading U.S. cancer centers devoted to patient care, research, and education. The NCCN Guidelines are the recognized standard for clinical direction and policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. For more information visit: https://www.nccn.org/guidelines/guidelines-process/about-nccn-clinical-practice-guidelines.\nNCCN® and the NCCN Guidelines® are registered trademarks of National Comprehensive Cancer Network.\nAbout AMLAcute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow that affects myeloid cells, which normally develop into various types of mature blood cells. AML occurs primarily in adults and accounts for about 1 percent of all adult cancers. The American Cancer Society estimates that in the United States alone, there will be about 20,050 new cases, most in adults, in 2022.1 \nRelapsed AML affects about half of all patients who, following treatment and remission, experie...

More updates from Rigel Pharmaceuticals, Inc.